Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 62 publications
Immune Checkpoint Inhibition and the Evolving Multidisciplinary Management of Head and Neck Cutaneous Squamous Cell Carcinoma.
Journal: Practical radiation oncology
Published: July 21, 2026
Emerging Treatments and Novel Modalities in Head and Neck Cancers.
Journal: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
Published: June 02, 2026
Notably Off Key: Questioning the Clinical Benefit of Perioperative Immunotherapy for Resectable Head and Neck Squamous Cell Carcinoma After KEYNOTE-689.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: April 22, 2026
BIO26-042: Technology-Based Symptom Monitoring Intervention for Locally Advanced Head and Neck Cancer Patients Initiating Chemoradiation: A Pilot Study.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: April 16, 2026
HSR26-209: Technology-Based Symptom Monitoring Intervention for Locally Advanced Head and Neck Cancer Patients Initiating Chemoradiation: A Qualitative Study.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: April 16, 2026
HSR26-209: Technology-Based Symptom Monitoring Intervention for Locally Advanced Head and Neck Cancer Patients Initiating Chemoradiation: A Qualitative Study.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: March 31, 2026
BIO26-042: Technology-Based Symptom Monitoring Intervention for Locally Advanced Head and Neck Cancer Patients Initiating Chemoradiation: A Pilot Study.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: March 30, 2026
A phase 1 trial of HPV16 E7 T-cell receptor-engineered T cells in patients with relapsed/refractory HPV16-positive cancers (KITE-439 trial).
Journal: Frontiers in oncology
Published: February 11, 2026
BASECAMP-1 screening study: a model for efficient enrolment in precision oncology clinical trials.
Journal: BMJ oncology
Published: December 16, 2025
Durable Complete Response of a Delta-Like Ligand 3 Expressing Head and Neck Neuroendocrine Carcinoma to Tarlatamab.
Journal: JCO precision oncology
Published: December 10, 2025
Advancing Cell Therapies for Solid Tumors: A Pathway to Overcome Biological, Operational, and Regulatory Hurdles.
Journal: Transplantation and cellular therapy
Published: December 04, 2025
MDM2 Inhibition with Alrizomadlin (APG-115) in TP53 wild-type salivary gland cancers: a phase I clinical trial.
Journal: Nature communications
Published: September 26, 2025
Last Updated: 09/26/2026